Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
Lahoz C, Mostaza JM, Pintó X, de la Cruz JJ, Banegas JR, Pedro-Botet J; grupo de investigadores EDICONDIS-ULISEA. Lahoz C, et al. Among authors: pinto x. Clin Investig Arterioscler. 2015 Jan-Feb;27(1):1-8. doi: 10.1016/j.arteri.2014.04.001. Epub 2014 Jun 2. Clin Investig Arterioscler. 2015. PMID: 24882148 Spanish.
[Apolipoprotein E polymorphism and coronary disease].
Peña R, M Mostaza J, Lahoz C, Jiménez J, Subirats E, Pinto X, Taboada M, López-Pastor A, del Estudio RAP g. Peña R, et al. Among authors: pinto x. Med Clin (Barc). 2001 May 19;116(18):681-5. doi: 10.1016/s0025-7753(01)71952-5. Med Clin (Barc). 2001. PMID: 11412677 Spanish.
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Vilardell M, Pintó X, Civeira F, Hernández A, da Silva PM, Rodriguez-Botaro A, Zambón D, Lima J, Díaz C, Aristegui R, Sol JM, Chaves J, Hernández G; ATOMIX Investigators. Gómez-Gerique JA, et al. Among authors: pinto x. Atherosclerosis. 2002 Jun;162(2):245-51. doi: 10.1016/s0021-9150(01)00708-0. Atherosclerosis. 2002. PMID: 11996943 Clinical Trial.
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J; HDL Forum. Ascaso JF, et al. Among authors: pinto x. Am J Cardiovasc Drugs. 2004;4(5):299-314. doi: 10.2165/00129784-200404050-00003. Am J Cardiovasc Drugs. 2004. PMID: 15449972 Review.
Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X. Lahoz C, et al. Among authors: pinto x. Metabolism. 2005 Jun;54(6):741-7. doi: 10.1016/j.metabol.2004.12.020. Metabolism. 2005. PMID: 15931608 Clinical Trial.
438 results